Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery

Biological Psychiatry

Volumn 64, Issue 2, 2008, Pages 145-152

  Samaha, Anne Noël ^a   Reckless, Greg E ^a   Seeman, Philip ^b,c   Diwan, Mustansir ^a   Nobrega, José N ^a,b,c   Kapur, Shitij ^a,b,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; conditioned avoidance; D2 receptors; dopamine; kinetics; supersensitivity

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; PROTEIN C FOS;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BIOLOGICAL AVAILABILITY; CONDITIONING, CLASSICAL; CORPUS STRIATUM; DEXTROAMPHETAMINE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; HALOPERIDOL; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; KINETICS; MALE; METABOLIC CLEARANCE RATE; MOTOR ACTIVITY; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 45449103060     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.01.010     Document Type: Article

References (71)

1. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction (1997), Lippincott-Raven, Philadelphia
2. Ericson H., Radesater A.C., Servin E., Magnusson O., and Mohringe B. Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat. Pharmacol Toxicol 79 (1996) 277-286
3. Turrone P., Remington G., Kapur S., and Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry 57 (2005) 406-411
4. Turrone P., Remington G., Kapur S., and Nobrega J.N. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28 (2003) 1433-1439
5. Glenthoj B., Hemmingsen R., Allerup P., and Bolwig T.G. Intermittent versus continuous neuroleptic treatment in a rat model. Eur J Pharmacol 190 (1990) 275-286
6. Carey R.J., and DeVeaugh-Geiss J. Treatment schedule as a determinant of the development of tolerance to haloperidol. Psychopharmacology (Berl) 82 (1984) 164-167
7. Csernansky J.G., Bellows E.P., Barnes D.E., and Lombrozo L. Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: The effect of regular/intermittent dosing. Psychopharmacology (Berl) 101 (1990) 519-524
8. Kashihara K., Sato M., Fujiwara Y., Harada T., Ogawa T., and Otsuki S. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Biol Psychiatry 21 (1986) 650-656
9. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
10. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157 (2000) 514-520
11. Kapur S., Zipursky R.B., and Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156 (1999) 286-293
12. Wadenberg M.L., Kapur S., Soliman A., Jones C., and Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150 (2000) 422-429
13. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2005) 1854-1863
14. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
15. Samaha A.N., Seeman P., Stewart J., Rajabi H., and Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27 (2007) 2979-2986
16. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd ed. (1997), Academic, New York
17. Ljungberg T., and Ungerstedt U. A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23 (1985) 479-485
18. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283 (1995) 55-62
19. Li M., Fletcher P.J., and Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32 (2006) 263-272
20. Wadenberg M.L., and Hicks P.B. The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev 23 (1999) 851-862
21. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
22. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51 (1982) 321-329
23. Kuribara H., and Tadokoro S. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 14 (1981) 181-192
24. Flores G., Barbeau D., Quirion R., and Srivastava L.K. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 16 (1996) 2020-2026
25. Pierce R.C., Rowlett J.K., Bardo M.T., and Rebec G.V. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding. Neuroscience 45 (1991) 373-378
26. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102 (2005) 3513-3518
27. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006) 319-346
28. Semba J., Sakai M.W., Suhara T., and Akanuma N. Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization. Neurochem Int 34 (1999) 269-277
29. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., and Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J Pharmacol Exp Ther 271 (1994) 460-471
30. Sebens J.B., Koch T., Ter Horst G.J., and Korf J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol 273 (1995) 175-182
31. Miller J.C. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem 54 (1990) 1453-1455
32. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271 (1994) 1058-1066
33. Natesan S., Svensson K.A., Reckless G.E., Nobrega J.N., Barlow K.B., Johansson A.M., and Kapur S. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318 (2006) 810-818
34. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 54 (1990) 1755-1760
35. Moghaddam B., and Bunney B.S. Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 14 suppl (1990) S51-S57
36. Drew K.L., O'Connor W.T., Kehr J., and Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur J Pharmacol 187 (1990) 385-397
37. Ichikawa J., and Meltzer H.Y. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 574 (1992) 98-104
38. Moore H., Todd C.L., and Grace A.A. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci 18 (1998) 5068-5077
39. Ichikawa J., and Meltzer H.Y. The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur J Pharmacol 176 (1990) 371-374
40. Lane R.F., and Blaha C.D. Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: Depolarization block as a possible mechanism of action. Brain Res Bull 18 (1987) 135-138
41. Hernandez L., and Hoebel B.G. Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res Bull 22 (1989) 763-769
42. See R.E., and Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol 263 (1994) 269-276
43. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14 (1994) 4159-4166
44. See R.E., and Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport 6 (1995) 1795-1798
45. Hussain N., Flumerfelt B.A., and Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 102 (2001) 391-399
46. Boegman R.J., and Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22 (1996) 70-77
47. Dragunow M., Robertson G.S., Faull R.L., Robertson H.A., and Jansen K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37 (1990) 287-294
48. Post R.M. Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or tolerance. Life Sci 26 (1980) 1275-1282
49. Reith M.E., Benuck M., and Lajtha A. Cocaine disposition in the brain after continuous or intermittent treatment and locomotor stimulation in mice. J Pharmacol Exp Ther 243 (1987) 281-287
50. Lau C.E., Imam A., Ma F., and Falk J.L. Acute effects of cocaine on spontaneous and discriminative motor functions: Relation to route of administration and pharmacokinetics. J Pharmacol Exp Ther 257 (1991) 444-456
51. Lillrank S.M., Oja S.S., Saransaari P., and Seppala T. Animal models of amphetamine psychosis: Neurotransmitter release from rat brain slices. Int J Neurosci 60 (1991) 1-15
52. Nelson L.R., and Ellison G. Enhanced stereotypies after repeated injections but not continuous amphetamines. Neuropharmacology 17 (1978) 1081-1084
53. King G.R., Joyner C., Lee T., Kuhn C., and Ellinwood Jr. E.H. Intermittent and continuous cocaine administration: Residual behavioral states during withdrawal. Pharmacol Biochem Behav 43 (1992) 243-248
54. Martin-Iverson M.T., and Burger L.Y. Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Mol Neurobiol 11 (1995) 31-46
55. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25 (1989) 473-478
56. Gnanalingham K.K., and Robertson R.G. The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study. Brain Res 640 (1994) 185-194
57. Engber T.M., Susel Z., Juncos J.L., and Chase T.N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168 (1989) 291-298
58. Samaha A.N., Li Y., and Robinson T.E. The rate of intravenous cocaine administration determines susceptibility to sensitization. J Neurosci 22 (2002) 3244-3250
59. Samaha A.N., Mallet N., Ferguson S.M., Gonon F., and Robinson T.E. The rate of cocaine administration alters gene regulation and behavioral plasticity: Implications for addiction. J Neurosci 24 (2004) 6362-6370
60. Samaha A.N., Yau W.Y., Yang P., and Robinson T.E. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. Biol Psychiatry 57 (2005) 351-360
61. Liu Y., Roberts D.C., and Morgan D. Sensitization of the reinforcing effects of self-administered cocaine in rats: Effects of dose and intravenous injection speed. Eur J Neurosci 22 (2005) 195-200
62. Jolley A.G., and Hirsch S.R. Continuous versus intermittent neuroleptic therapy in schizophrenia. Drug Saf 8 (1993) 331-339
63. Peuskens J. Proper psychosocial rehabilitation for stabilised patients with schizophrenia: The role of new therapies. Eur Neuropsychopharmacol 6 suppl 2 (1996) S7-S12
64. Schooler N.R. Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophr Bull 17 (1991) 311-324
65. Carpenter Jr. W.T., Buchanan R.W., Kirkpatrick B., Lann H.D., Breier A.F., and Summerfelt A.T. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 156 (1999) 412-418
66. Jolley A.G., Hirsch S.R., Morrison E., McRink A., and Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. BMJ 301 (1990) 837-842
67. Gaebel W. Intermittent medication-an alternative?. Acta Psychiatr Scand Suppl 382 (1994) 33-38
68. Gaebel W., Janner M., Frommann N., Pietzcker A., Kopcke W., Linden M., et al. First vs multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53 (2002) 145-159
69. Remington G., Seeman P., Shammi C., Mann S., and Kapur S. "Extended" antipsychotic dosing: Rationale and pilot data. J Clin Psychopharmacol 25 (2005) 611-613
70. Li M., Parkes J., Fletcher P.J., and Kapur S. Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78 (2004) 811-819
71. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., and Seeman P. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57 (2000) 553-559